Drug-induced pulmonary toxicity in breast cancer patients treated with systemic therapy: a systematic literature review-Reference-Cited by-同舟云学术

Drug-induced pulmonary toxicity in breast cancer patients treated with systemic therapy: a systematic literature review

Published:2021-11-02 Issue:12 Volume:21 Page:1399-1410
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Chen Shanshan¹,Ren Yanhong²,Dai Huaping²,Li Yiqun¹,Lan Bo¹,Ma Fei¹

Affiliation:

1. Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China

2. Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, National Center for Respiratory Medicine; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, National Clinical Research Center for Respiratory Disease, Beijing, China

Funder

Astra Zeneca, China

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2021.1996229

Reference77 articles.

1. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

2. Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study

3. Pembrolizumab for Early Triple-Negative Breast Cancer

4. Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer--96-Month Follow-up of the Randomized IBIS-I Trial

5. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial